{
  "id": 4,
  "text": "d the \ninvestment of excess liquidity. The Group's \nTreasury identifies, assesses and covers \nfinancial risks in close cooperation with the \nCompany. More details on the management of financial \nrisks are available in the chapter FINANCIAL \nRISKS (ARTICLES 3: 6, 1, 8 AND 3:32, 1, 5, OF THE BCAC) of the consolidated financial \nstatements, see page 162. Significants acquisitions and divestments in \n2023 \nIn Febrary 2023, the group acquired Fluidomica \nLD.A. This entity produces Target Solutions for \nMedical Radioisopes Market. IBA also acquired a minority stake in Invest.BW \nS.A, a venture capital partner supporting the \neconomic development in the Walloon Region.",
  "similarity_score": 0.06028093494262701,
  "metadata": {
    "filename": "annual_report_text (1).txt",
    "filepath": "input\\annual_report_text (1).txt",
    "chunk_id": 561,
    "start_char_idx": 0,
    "end_char_idx": 0,
    "page": null,
    "section": null
  }
}